Almirall stock holds steady as investors digest H1 2026 results
Published on 08/27/2026 at 12:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock is trading close to recent levels in late August 2026 as investors weigh the Spanish pharmaceutical company’s first-half 2026 performance and its positioning for the rest of the year (ISIN ES0157097017).
Market performance as of August 2026
Per a recent market overview as of August 17, 2026, Almirall shares were quoted at EUR 10.48 on the Madrid exchange, with the stock showing a year-to-date return of -17.43 percent and a one-year return of -4.04 percent, compared with gains of 15.99 percent and 31.76 percent, respectively, for the IBEX 35 index.
Those relative returns highlight that the stock has lagged the broader Spanish market in 2026, even though it remains positive over a three-year horizon, with a total return of 19.63 percent over that period while the IBEX 35 gained 116.96 percent.
Recent financial results and outlook
In its first-half 2026 reporting, Almirall presented consolidated results for the period ending in mid-2026, giving investors an updated view of revenue, earnings and profitability during a year of continued investment in dermatology and immunology.
Management’s latest communication for H1 2026 indicated that the company continues to execute its strategy while navigating competitive pressures and pricing dynamics in key markets, with guidance for the remainder of 2026 focused on balancing growth and profitability.
Dermatology portfolio and pipeline
Almirall has built its recent growth strategy around prescription dermatology, including treatments for chronic skin conditions, inflammatory diseases and related indications, and the first-half 2026 period remained centered on expanding this portfolio in Europe and other priority regions.
Alongside marketed products, the company’s pipeline includes late-stage and mid-stage dermatology and immunology assets that are intended to support medium-term revenue growth beyond 2026.
Stock perspective heading into late 2026
With Almirall stock trading at EUR 10.48 as of August 17, 2026 in the referenced market snapshot and showing a negative year-to-date return versus a rising IBEX 35, investors are likely to focus on whether upcoming quarters can deliver a turnaround in relative performance.
The key variables will include the pace of revenue expansion in core dermatology franchises, the impact of any new product launches, and the company’s ability to sustain or improve margins after the first-half 2026 period.
Fact box
Company: Almirall, S.A.
ISIN: ES0157097017
Ticker: ALM
Exchange: BME (Madrid)
Price (as of August 17, 2026): EUR 10.48
Sector / Industry: Pharmaceuticals / Biotechnology
